{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:32:14Z","timestamp":1790397134327,"version":"4.1.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T00:00:00Z","timestamp":1667779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T00:00:00Z","timestamp":1667779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"NIH","award":["R01AG066159"],"award-info":[{"award-number":["R01AG066159"]}]},{"name":"NIH","award":["R56AG047992"],"award-info":[{"award-number":["R56AG047992"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Metab Brain Dis"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s11011-022-01114-1","type":"journal-article","created":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T03:10:54Z","timestamp":1667790654000},"page":"185-193","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Blood-based biomarkers in Alzheimer\u2019s disease: a mini-review"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5078-8869","authenticated-orcid":false,"given":"Sanjana P.","family":"Padala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9298-7185","authenticated-orcid":false,"given":"Paul A.","family":"Newhouse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,7]]},"reference":[{"key":"1114_CR1","doi-asserted-by":"publisher","unstructured":"Benedet AL, Mila-Aloma M, Vrillon A, Ashton NJ, Pascoal TA, Lussier F, . . ., BioCogBank Paris Lariboisiere c (2021) Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the alzheimer disease continuum. JAMA Neurol 78(12): 1471\u20131483. https:\/\/doi.org\/10.1001\/jamaneurol.2021.3671","DOI":"10.1001\/jamaneurol.2021.3671"},{"issue":"3","key":"1114_CR2","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1067\/mcp.2001.113989","volume":"69","author":"Biomarkers Definitions Working, G","year":"2001","unstructured":"Biomarkers Definitions Working, G (2001) Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69(3):89\u201395. https:\/\/doi.org\/10.1067\/mcp.2001.113989","journal-title":"Clin Pharmacol Ther"},{"key":"1114_CR3","doi-asserted-by":"publisher","first-page":"345","DOI":"10.3389\/fnins.2015.00345","volume":"9","author":"K Blennow","year":"2015","unstructured":"Blennow K, Zetterberg H (2015) The past and the future of Alzheimer\u2019s disease CSF biomarkers-a journey toward validated biochemical tests covering the whole spectrum of molecular events. Front Neurosci 9:345. https:\/\/doi.org\/10.3389\/fnins.2015.00345","journal-title":"Front Neurosci"},{"issue":"Suppl 2","key":"1114_CR4","doi-asserted-by":"publisher","first-page":"S65","DOI":"10.1007\/s100720200072","volume":"23","author":"S Calzetti","year":"2002","unstructured":"Calzetti S, Bortone E, Negrotti A, Zinno L, Mancia D (2002) Frontal intermittent rhythmic delta activity (FIRDA) in patients with dementia with Lewy bodies: a diagnostic tool? Neurol Sci 23(Suppl 2):S65-66. https:\/\/doi.org\/10.1007\/s100720200072","journal-title":"Neurol Sci"},{"key":"1114_CR5","doi-asserted-by":"publisher","unstructured":"Chen YR, Liang CS, Chu H, Voss J, Kang XL, O'Connell G, . . ., Chou KR (2021) Diagnostic accuracy of blood biomarkers for Alzheimer's disease and amnestic mild cognitive impairment: a meta-analysis. Ageing Res Rev 71: 101446. https:\/\/doi.org\/10.1016\/j.arr.2021.101446","DOI":"10.1016\/j.arr.2021.101446"},{"issue":"1","key":"1114_CR6","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s13195-021-00838-z","volume":"13","author":"J Cummings","year":"2021","unstructured":"Cummings J, Aisen P, Lemere C, Atri A, Sabbagh M, Salloway S (2021) Aducanumab produced a clinically meaningful benefit in association with amyloid lowering. Alzheimers Res Ther 13(1):98. https:\/\/doi.org\/10.1186\/s13195-021-00838-z","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"1114_CR7","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1136\/jnnp.2010.216432","volume":"82","author":"H de Waal","year":"2011","unstructured":"de Waal H, Stam CJ, Blankenstein MA, Pijnenburg YA, Scheltens P, van der Flier WM (2011) EEG abnormalities in early and late onset Alzheimer\u2019s disease: understanding heterogeneity. J Neurol Neurosurg Psychiatry 82(1):67\u201371. https:\/\/doi.org\/10.1136\/jnnp.2010.216432","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1114_CR8","doi-asserted-by":"publisher","unstructured":"Dhiman K, Gupta VB, Villemagne VL, Eratne D, Graham PL, Fowler C, . . ., Martins RN (2020) Cerebrospinal fluid neurofilament light concentration predicts brain atrophy and cognition in Alzheimer's disease. Alzheimers Dement (Amst) 12(1): e12005. https:\/\/doi.org\/10.1002\/dad2.12005","DOI":"10.1002\/dad2.12005"},{"key":"1114_CR9","doi-asserted-by":"publisher","unstructured":"Duits FH, Martinez-Lage P, Paquet C, Engelborghs S, Lleo A, Hausner L, . . ., Blennow K (2016) Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lumbar puncture feasibility study. Alzheimers Dement 12(2): 154\u2013163. https:\/\/doi.org\/10.1016\/j.jalz.2015.08.003","DOI":"10.1016\/j.jalz.2015.08.003"},{"key":"1114_CR10","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.neurobiolaging.2017.05.017","volume":"57","author":"AA Gouw","year":"2017","unstructured":"Gouw AA, Alsema AM, Tijms BM, Borta A, Scheltens P, Stam CJ, van der Flier WM (2017) EEG spectral analysis as a putative early prognostic biomarker in nondemented, amyloid positive subjects. Neurobiol Aging 57:133\u2013142. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2017.05.017","journal-title":"Neurobiol Aging"},{"key":"1114_CR11","doi-asserted-by":"publisher","unstructured":"Honig LS, Vellas B, Woodward M, Boada M, Bullock R, Borrie M, . . ., Siemers E (2018) Trial of solanezumab for mild dementia due to Alzheimer's disease. N Engl J Med 378(4): 321\u2013330. https:\/\/doi.org\/10.1056\/NEJMoa1705971","DOI":"10.1056\/NEJMoa1705971"},{"key":"1114_CR12","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/j.1749-6632.1996.tb34420.x","volume":"777","author":"M Hull","year":"1996","unstructured":"Hull M, Berger M, Volk B, Bauer J (1996) Occurrence of interleukin-6 in cortical plaques of Alzheimer\u2019s disease patients may precede transformation of diffuse into neuritic plaques. Ann N Y Acad Sci 777:205\u2013212. https:\/\/doi.org\/10.1111\/j.1749-6632.1996.tb34420.x","journal-title":"Ann N Y Acad Sci"},{"key":"1114_CR13","doi-asserted-by":"publisher","unstructured":"Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, . . ., Contributors (2018) NIA-AA Research Framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement 14(4): 535\u2013562. https:\/\/doi.org\/10.1016\/j.jalz.2018.02.018","DOI":"10.1016\/j.jalz.2018.02.018"},{"key":"1114_CR14","doi-asserted-by":"publisher","unstructured":"Jack CR Jr, Petersen RC, Xu YC, O'Brien PC, Smith GE, Ivnik RJ, . . ., Kokmen E (1999) Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology 52(7): 1397\u20131403. https:\/\/doi.org\/10.1212\/wnl.52.7.1397","DOI":"10.1212\/wnl.52.7.1397"},{"key":"1114_CR15","doi-asserted-by":"publisher","unstructured":"Jansen WJ, Janssen O, Tijms BM, Vos SJB, Ossenkoppele R, Visser PJ, . . ., Zetterberg H (2022) prevalence estimates of amyloid abnormality across the Alzheimer disease clinical spectrum. JAMA Neurol. https:\/\/doi.org\/10.1001\/jamaneurol.2021.5216","DOI":"10.1001\/jamaneurol.2021.5216"},{"key":"1114_CR16","doi-asserted-by":"publisher","unstructured":"Kemppainen NM, Aalto S, Wilson IA, Nagren K, Helin S, Bruck A, . . ., Rinne JO (2007) PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment. Neurology 68(19): 1603\u20131606. https:\/\/doi.org\/10.1212\/01.wnl.0000260969.94695.56","DOI":"10.1212\/01.wnl.0000260969.94695.56"},{"key":"1114_CR17","doi-asserted-by":"publisher","unstructured":"Keshavan A, Pannee J, Karikari TK, Rodriguez JL, Ashton NJ, Nicholas JM, . . ., Schott JM (2021) Population-based blood screening for preclinical Alzheimer's disease in a British birth cohort at age 70. Brain 144(2): 434\u2013449. https:\/\/doi.org\/10.1093\/brain\/awaa403","DOI":"10.1093\/brain\/awaa403"},{"key":"1114_CR18","doi-asserted-by":"publisher","unstructured":"Kirmess KM, Meyer MR, Holubasch MS, Knapik SS, Hu Y, Jackson EN, . . ., Contois JH (2021) The PrecivityAD test: accurate and reliable LC-MS\/MS assays for quantifying plasma amyloid beta 40 and 42 and apolipoprotein E proteotype for the assessment of brain amyloidosis. Clin Chim Acta 519: 267\u2013275. https:\/\/doi.org\/10.1016\/j.cca.2021.05.011","DOI":"10.1016\/j.cca.2021.05.011"},{"issue":"2","key":"1114_CR19","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1176\/appi.focus.20170048","volume":"16","author":"AM Koenig","year":"2018","unstructured":"Koenig AM, Nobuhara CK, Williams VJ, Arnold SE (2018) Biomarkers in Alzheimer\u2019s, frontotemporal, lewy body, and vascular dementias. Focus (am Psychiatr Publ) 16(2):164\u2013172. https:\/\/doi.org\/10.1176\/appi.focus.20170048","journal-title":"Focus (am Psychiatr Publ)"},{"issue":"1","key":"1114_CR20","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s40035-020-00221-2","volume":"9","author":"HS Kwon","year":"2020","unstructured":"Kwon HS, Koh SH (2020) Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes. Transl Neurodegener 9(1):42. https:\/\/doi.org\/10.1186\/s40035-020-00221-2","journal-title":"Transl Neurodegener"},{"key":"1114_CR21","doi-asserted-by":"publisher","unstructured":"Landau SM, Harvey D, Madison CM, Koeppe RA, Reiman EM, Foster NL, . . ., Alzheimer's Disease Neuroimaging, I (2011) Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging 32(7): 1207\u20131218. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2009.07.002","DOI":"10.1016\/j.neurobiolaging.2009.07.002"},{"key":"1114_CR22","doi-asserted-by":"publisher","unstructured":"Leuzy A, Smith R, Cullen NC, Strandberg O, Vogel JW, Binette AP, . . ., Hansson O (2022) Biomarker-based prediction of longitudinal tau positron emission tomography in Alzheimer disease. JAMA Neurol 79(2): 149\u2013158. https:\/\/doi.org\/10.1001\/jamaneurol.2021.4654","DOI":"10.1001\/jamaneurol.2021.4654"},{"key":"1114_CR23","doi-asserted-by":"publisher","unstructured":"Mattsson N, Zetterberg H, Janelidze S, Insel PS, Andreasson U, Stomrud E, . . ., Investigators, A (2016) Plasma tau in Alzheimer disease. Neurology 87(17): 1827\u20131835. https:\/\/doi.org\/10.1212\/WNL.0000000000003246","DOI":"10.1212\/WNL.0000000000003246"},{"issue":"2","key":"1114_CR24","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1602\/neurorx.1.2.182","volume":"1","author":"R Mayeux","year":"2004","unstructured":"Mayeux R (2004) Biomarkers: potential uses and limitations. NeuroRx 1(2):182\u2013188. https:\/\/doi.org\/10.1602\/neurorx.1.2.182","journal-title":"NeuroRx"},{"issue":"Suppl 1","key":"1114_CR25","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1016\/j.neurobiolaging.2011.09.004","volume":"32","author":"R Mayeux","year":"2011","unstructured":"Mayeux R, Schupf N (2011) Blood-based biomarkers for Alzheimer\u2019s disease: plasma Abeta40 and Abeta42, and genetic variants. Neurobiol Aging 32(Suppl 1):S10-19. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2011.09.004","journal-title":"Neurobiol Aging"},{"key":"1114_CR26","doi-asserted-by":"publisher","unstructured":"McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, . . ., Phelps CH (2011) The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7(3): 263\u2013269. https:\/\/doi.org\/10.1016\/j.jalz.2011.03.005","DOI":"10.1016\/j.jalz.2011.03.005"},{"key":"1114_CR27","doi-asserted-by":"publisher","unstructured":"Mielke MM, Frank RD, Dage JL, Jeromin A, Ashton NJ, Blennow K, . . ., Petersen RC (2021) Comparison of plasma phosphorylated tau species with amyloid and tau positron emission tomography, neurodegeneration, vascular pathology, and cognitive outcomes. JAMA Neurol 78(9): 1108\u20131117. https:\/\/doi.org\/10.1001\/jamaneurol.2021.2293","DOI":"10.1001\/jamaneurol.2021.2293"},{"key":"1114_CR28","doi-asserted-by":"publisher","unstructured":"Morgan AR, Touchard S, Leckey C, O'Hagan C, Nevado-Holgado AJ, Consortium, N, . . ., Alzheimer's, D (2019) Inflammatory biomarkers in Alzheimer's disease plasma. Alzheimers Dement 15(6): 776\u2013787. https:\/\/doi.org\/10.1016\/j.jalz.2019.03.007","DOI":"10.1016\/j.jalz.2019.03.007"},{"issue":"4","key":"1114_CR29","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1007\/s00259-005-1762-7","volume":"32","author":"L Mosconi","year":"2005","unstructured":"Mosconi L (2005) Brain glucose metabolism in the early and specific diagnosis of Alzheimer\u2019s disease. FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging 32(4):486\u2013510. https:\/\/doi.org\/10.1007\/s00259-005-1762-7","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1114_CR30","doi-asserted-by":"publisher","unstructured":"Nabers A, Perna L, Lange J, Mons U, Schartner J, Guldenhaupt J, . . ., Brenner H (2018) Amyloid blood biomarker detects Alzheimer's disease. EMBO Mol Med 10(5). https:\/\/doi.org\/10.15252\/emmm.201708763","DOI":"10.15252\/emmm.201708763"},{"key":"1114_CR31","doi-asserted-by":"publisher","first-page":"46","DOI":"10.12703\/r\/10-46","volume":"10","author":"S Narayanan","year":"2021","unstructured":"Narayanan S, Shanker A, Khera T, Subramaniam B (2021) Neurofilament light: a narrative review on biomarker utility. Fac Rev 10:46. https:\/\/doi.org\/10.12703\/r\/10-46","journal-title":"Fac Rev"},{"key":"1114_CR32","doi-asserted-by":"publisher","unstructured":"Olson BL, Holshouser BA, Britt W 3rd, Mueller C, Baqai W, Patra S, . . ., Kirsch WM (2008) Longitudinal metabolic and cognitive changes in mild cognitive impairment patients. Alzheimer Dis Assoc Disord 22(3): 269\u2013277. https:\/\/doi.org\/10.1097\/WAD.0b013e3181750a65","DOI":"10.1097\/WAD.0b013e3181750a65"},{"key":"1114_CR33","doi-asserted-by":"publisher","unstructured":"Osborn KE, Khan OA, Kresge HA, Bown CW, Liu D, Moore EE, . . ., Jefferson AL (2019) Cerebrospinal fluid and plasma neurofilament light relate to abnormal cognition. Alzheimers Dement (Amst) 11: 700-709. https:\/\/doi.org\/10.1016\/j.dadm.2019.08.008","DOI":"10.1016\/j.dadm.2019.08.008"},{"key":"1114_CR34","doi-asserted-by":"publisher","unstructured":"Ovod V, Ramsey KN, Mawuenyega KG, Bollinger JG, Hicks T, Schneider T, . . ., Bateman RJ (2017) Amyloid beta concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimers Dement 13(8): 841\u2013849. https:\/\/doi.org\/10.1016\/j.jalz.2017.06.2266","DOI":"10.1016\/j.jalz.2017.06.2266"},{"key":"1114_CR35","doi-asserted-by":"publisher","unstructured":"Palmqvist S, Insel PS, Stomrud E, Janelidze S, Zetterberg H, Brix B, . . ., Hansson O (2019) Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease. EMBO Mol Med 11(12): e11170. https:\/\/doi.org\/10.15252\/emmm.201911170","DOI":"10.15252\/emmm.201911170"},{"key":"1114_CR36","doi-asserted-by":"publisher","unstructured":"Palmqvist S, Tideman P, Cullen N, Zetterberg H, Blennow K, Alzheimer's Disease Neuroimaging, I, . . . Hansson O (2021) Prediction of future Alzheimer's disease dementia using plasma phospho-tau combined with other accessible measures. Nat Med 27(6): 1034\u20131042. https:\/\/doi.org\/10.1038\/s41591-021-01348-z","DOI":"10.1038\/s41591-021-01348-z"},{"key":"1114_CR37","doi-asserted-by":"publisher","unstructured":"Perez-Grijalba V, Romero J, Pesini P, Sarasa L, Monleon I, San-Jose I, . . ., Sarasa M (2019) Plasma Abeta42\/40 ratio detects early stages of Alzheimer's disease and correlates with CSF and neuroimaging biomarkers in the AB255 Study. J Prev Alzheimers Dis 6(1): 34\u201341. https:\/\/doi.org\/10.14283\/jpad.2018.41","DOI":"10.14283\/jpad.2018.41"},{"key":"1114_CR38","doi-asserted-by":"publisher","unstructured":"Pillai JA, Bena J, Bebek G, Bekris LM, Bonner-Jackson A, Kou L, . . ., Alzheimer's Disease Neuroimaging, I (2020) Inflammatory pathway analytes predicting rapid cognitive decline in MCI stage of Alzheimer's disease. Ann Clin Transl Neurol 7(7): 1225\u20131239. https:\/\/doi.org\/10.1002\/acn3.51109","DOI":"10.1002\/acn3.51109"},{"key":"1114_CR39","doi-asserted-by":"publisher","unstructured":"Preische O, Schultz SA, Apel A, Kuhle J, Kaeser SA, Barro C, . . ., Dominantly Inherited Alzheimer, N (2019) Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease. Nat Med 25(2): 277\u2013283. https:\/\/doi.org\/10.1038\/s41591-018-0304-3","DOI":"10.1038\/s41591-018-0304-3"},{"issue":"4","key":"1114_CR40","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1055\/s-0033-1359312","volume":"33","author":"SL Risacher","year":"2013","unstructured":"Risacher SL, Saykin AJ (2013) Neuroimaging biomarkers of neurodegenerative diseases and dementia. Semin Neurol 33(4):386\u2013416. https:\/\/doi.org\/10.1055\/s-0033-1359312","journal-title":"Semin Neurol"},{"issue":"1","key":"1114_CR41","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13024-021-00452-5","volume":"16","author":"M Seto","year":"2021","unstructured":"Seto M, Weiner RL, Dumitrescu L, Hohman TJ (2021) Protective genes and pathways in Alzheimer\u2019s disease: moving towards precision interventions. Mol Neurodegener 16(1):29. https:\/\/doi.org\/10.1186\/s13024-021-00452-5","journal-title":"Mol Neurodegener"},{"key":"1114_CR42","unstructured":"Sobow T, Flirski M, Kloszewska I, Liberski PP (2005) Plasma levels of alpha beta peptides are altered in amnestic mild cognitive impairment but not in sporadic Alzheimer's disease. Acta Neurobiol Exp (Wars) 65(2): 117\u2013124. Retrieved from.\u00a0https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/15960295. Accessed 03\/26\/2022"},{"key":"1114_CR43","doi-asserted-by":"publisher","unstructured":"Swanson CJ, Zhang Y, Dhadda S, Wang J, Kaplow J, Lai RYK, . . ., Cummings JL (2021) A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Abeta protofibril antibody. Alzheimers Res Ther 13(1): 80. https:\/\/doi.org\/10.1186\/s13195-021-00813-8","DOI":"10.1186\/s13195-021-00813-8"},{"issue":"3","key":"1114_CR44","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1001\/archneurol.2008.596","volume":"66","author":"T Tapiola","year":"2009","unstructured":"Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, Soininen H, Pirttila T (2009) Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol 66(3):382\u2013389. https:\/\/doi.org\/10.1001\/archneurol.2008.596","journal-title":"Arch Neurol"},{"issue":"3","key":"1114_CR45","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/s0361-9230(03)00088-1","volume":"61","author":"E Tarkowski","year":"2003","unstructured":"Tarkowski E, Liljeroth AM, Minthon L, Tarkowski A, Wallin A, Blennow K (2003) Cerebral pattern of pro- and anti-inflammatory cytokines in dementias. Brain Res Bull 61(3):255\u2013260. https:\/\/doi.org\/10.1016\/s0361-9230(03)00088-1","journal-title":"Brain Res Bull"},{"key":"1114_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2021.105250","volume":"152","author":"S Tumati","year":"2022","unstructured":"Tumati S, Herrmann N, Marotta G, Li A, Lanctot KL (2022) Blood-based biomarkers of agitation in Alzheimer\u2019s disease: Advances and future prospects. Neurochem Int 152:105250. https:\/\/doi.org\/10.1016\/j.neuint.2021.105250","journal-title":"Neurochem Int"},{"issue":"10","key":"1114_CR47","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0223832","volume":"14","author":"CM Umemneku Chikere","year":"2019","unstructured":"Umemneku Chikere CM, Wilson K, Graziadio S, Vale L, Allen AJ (2019) Diagnostic test evaluation methodology: A systematic review of methods employed to evaluate diagnostic tests in the absence of gold standard - an update. PLoS One 14(10):e0223832. https:\/\/doi.org\/10.1371\/journal.pone.0223832","journal-title":"PLoS ONE"},{"key":"1114_CR48","doi-asserted-by":"publisher","unstructured":"West T, Kirmess KM, Meyer MR, Holubasch MS, Knapik SS, Hu Y, . . ., Yarasheski KE (2021) A blood-based diagnostic test incorporating plasma Abeta42\/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis. Mol Neurodegener 16(1): 30. https:\/\/doi.org\/10.1186\/s13024-021-00451-6","DOI":"10.1186\/s13024-021-00451-6"},{"issue":"1","key":"1114_CR49","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13041-019-0448-1","volume":"12","author":"H Zetterberg","year":"2019","unstructured":"Zetterberg H, Burnham SC (2019) Blood-based molecular biomarkers for Alzheimer\u2019s disease. Mol Brain 12(1):26. https:\/\/doi.org\/10.1186\/s13041-019-0448-1","journal-title":"Mol Brain"}],"container-title":["Metabolic Brain Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11011-022-01114-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11011-022-01114-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11011-022-01114-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,14]],"date-time":"2023-01-14T22:17:02Z","timestamp":1673734622000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11011-022-01114-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,7]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["1114"],"URL":"https:\/\/doi.org\/10.1007\/s11011-022-01114-1","relation":{},"ISSN":["0885-7490","1573-7365"],"issn-type":[{"value":"0885-7490","type":"print"},{"value":"1573-7365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,7]]},"assertion":[{"value":"26 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Both authors (Padala and Newhouse) have no conflicts of interest\/competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/Competing interests"}}]}}